New Oral Therapy ICOTYDE Approved for Psoriasis, Offering Hope and Improved Quality of Life
The U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), a first-of-its-kind oral treatment for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg. This approval marks a significant advancement in psoriasis treatment, offering a new option for those who are candidates for systemic therapy or phototherapy. Johnson & Johnson announced the approval on March 18, 2026.
Understanding Plaque Psoriasis
Plaque psoriasis, the most common form of the condition, affects approximately 80% to 90% of individuals with psoriasis. It is characterized by thick, scaly patches on the skin, often appearing on the elbows, knees, scalp, and back. These plaques can be itchy and painful, significantly impacting a patient’s quality of life.
The Emotional Toll of Psoriasis
Living with psoriasis can extend beyond physical discomfort, taking a substantial emotional toll, particularly during adolescence. Maddox Patt, now 27, was diagnosed with plaque psoriasis at age 12. He shared his experience, describing the difficulty of navigating teenage years while coping with visible skin lesions.
“It was very difficult to walk around and have these large, scaly, red masses on my body and my face,” Patt said. He described feeling compelled to conceal his condition, wearing long sleeves even in warm weather and preferring to go out at night. “It takes a large, emotional toll on you. It was very difficult to live and to be out in the world and experience things.”
How ICOTYDE Works
ICOTYDE is an interleukin-23 (IL-23) receptor antagonist. IL-23 plays a key role in the inflammatory processes that drive psoriasis. By blocking the IL-23 receptor, ICOTYDE helps to reduce inflammation and alleviate psoriasis symptoms. The medication is administered as a once-daily pill, offering a convenient alternative to injectable biologics.
Clinical Trial Results
The approval of ICOTYDE is based on data from the ICONIC clinical development program, which involved four phase 3 studies with over 2,500 participants. Results demonstrated that ICOTYDE achieved “biologic-level efficacy” with a convenient once-daily oral administration.
In head-to-head studies, ICOTYDE showed superior skin clearance compared to Bristol Myers Squibb’s Sotyktu at both week 16 and week 24, with benefits sustained through week 52. Approximately 70% of patients treated with ICOTYDE achieved clear or almost clear skin, and over half (55%) experienced a Psoriasis Area and Severity Index (PASI) 90 response – a 90% improvement in disease severity.
A New Era in Psoriasis Treatment
ICOTYDE represents a “potential game-changer” for many patients, aligning with evolving treatment guidelines that recommend early systemic therapy for those who haven’t responded to topical treatments. For individuals like Maddox Patt, who participated in a clinical trial, ICOTYDE has offered significant relief and a renewed sense of well-being. “I’m feeling great. It’s like a night and day difference,” Patt stated. “I’m not walking around with big, bloody sores and feeling itchy all the time.”
Patt likewise highlighted the importance of clinical trials in providing access to cutting-edge medications, particularly in a healthcare landscape where access to care can be challenging. “Psoriasis is a quality-of-life thing, it’s not a life-ending disease, but being able to participate in clinical trials can be really, really helpful for a lot of people.”